VACC 100

Call to the Scientific Community and BioTech Industry to Participate in the Upgrade Cellular Cancer Vaccines

Biobohemia announced call for participation in the cancer vaccines upgrade initiative (Vacc 100). The upgrade comprises development of analogs of cellular cancer vaccines using antigenic essence technology. Individual scientists, groups, institutes, foundations, sponsors, advisers, legal companies, and incubators are invited. Several tens vaccines are planned to be upgraded. The scientific basis for such an upgrade is summarized in a recent publication ("Antigenic essence: upgrade of cellular cancer vaccines", Cancers, 2021, 13, 774). The initiative aims to consolidate academic science with the financial capabilities of investors. Organizers of the initiative will provide coordination and support to participants.

In July 2021, the results of this challenge will be summarized and the initial list of participants in the initiative will be published. Information will also be provided on which organizations are developing the antigenic essence vaccines and against which cancer types, and which organizations are participating in a supportive role.

The online application form for participation in the initiative is presented below.
Also offline pdf application form is available, you can fill it out and send it to our Email: vacc100@biobohemia.com

Download application form

APPLICATION FORM

for participation in VACC 100 initiative

Specify possible types of participation in the initiative for your organization (check appropriate boxes or provide information in the 'other' text box).

Intellectual property

Provision of licenses to participants in the initiative

Analytical services

Mass spectrometry analysis of antigenic essences
Development and standardization of protocols for mass spectrometry analysis of antigenic essences

Bioinformatic treatment

Encoding of mass spectrometry data (obtaining antigenic essence codes)
Model development
Prediction of essence composition with determined immunogenicity and similarity to the antigenic profile of target cells

Database resources

Storage of and providing access to antigenic essence codes

Quality control & quality assurance

Writing and adapting quality control and quality assurance programs

Cell banks

Providing master cell bank
Providing working cell bank systems used for the product manufacture

Manufacture

Design of manufacture
Build of manufacture
Production of antigenic essence

Clinical trial

Conduction of clinical trials

Legal services

Legal support for participants of the initiative

Sponsorship

Sponsorship

Other (specify the type of activity not listed above)

We confirm that we want to participate in the VACC 100 initiative, the scope of participation is determined by our interests, we ask to make us a member of this initiative, and we reserve the right to leave the initiative at any time.

We confirm that we are sharing the information provided in this application form with the organizer of the VACC 100 initiative (Biobohemia Inc.) for use under this initiative.

We would like to join the Consortium organized under this initiative.

We would like to receive information on the available licenses for the production of antigenic essence:

To acquire an exclusive license
To acquire a non-exclusive license
For informational purposes

We agree that information about us will be published in the scientific paper (or newspaper) dedicated to the VACC 100 initiative.

We agree that information about us will be available to other participants of the initiative (to coordinate initiative activities).

We want to receive press releases issued by the initiative.

We want to receive documents (such as "Information package of product", "Target product profile", information summary of "Chemistry, Manufacturing and Controls" (CMC)) shared by the organizers or other participants of the initiative.

We would like to receive financial support from sponsors of the initiative or other sources available within the initiative.

By clicking on the button, you consent to the "Privacy policy" and "Terms and conditions of use"

Forward-Looking Statements

This initiative "VACC 100" contains forward-looking statements. Such forward-looking statements can be identified by the use of the words "expect," "believe," "will," "anticipate," "estimate," "plan," "project" and other words of similar import. The forward-looking statements in this initiative "VACC 100" include, but are not limited to, statements related to the potential of clinical candidates as therapeutic options for various cancers, the general development of the product candidates pipeline and anticipated milestone dates, and the possible effects of the approach to cancer treatment. These forward-looking statements are based on current plans of Biobohemia, Inc., objectives, estimates, expectations, and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with immuno-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting companies and its development programs. Other risks and uncertainties of which Biobohemia, Inc. is not currently aware may also affect the Biobohemia, Inc. forward-looking statements. The forward-looking statements herein are made only as of the date hereof. Biobohemia, Inc. undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations, or other circumstances that exist after the date as of which the forward-looking statements were made. There are no any public offers in this declared initiative "VACC 100".